[1] | |
[2] |
YOUNOSSI Z, ANSTEE Q M, MARIETTI M, HARDY T, HENRY L, ESLAM M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2018, 15: 11-20. DOI:10.1038/nrgastro.2017.109 |
[3] |
ZHOU F, ZHOU J H, WANG W X, ZHANG X J, JI Y X, ZHANG P, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018:a systematic review and meta-analysis[J]. Hepatology, 2019, 70: 1119-1133. DOI:10.1002/hep.30702 |
[4] |
ARMSTRONG M J, ADAMS L A, CANBAY A, SYN W K. Extrahepatic complications of nonalcoholic fatty liver disease[J]. Hepatology, 2014, 59: 1174-1197. DOI:10.1002/hep.26717 |
[5] |
DAWSON-HUGHES B, STATEN M A, KNOWLER W C, NELSON J, VICKERY E M, LEBLANC E S, et al. Intratrial exposure to vitamin D and new-onset diabetes among adults with prediabetes: a secondary analysis from the vitamin D and type 2 diabetes (D2d) study[J]. Diabetes Care, 2020, 43: 2916-2922. DOI:10.2337/dc20-1765 |
[6] |
XING Y L, CHENG T T, ZHOU F, MA H J. The association between vitamin D and type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease: an observational cross-sectional study[J]. Diabetes Metab Syndr Obes, 2022, 15: 269-280. DOI:10.2147/DMSO.S348870 |
[7] |
JARUVONGVANICH V, AHUJA W, SANGUANKEO A, WIJARNPREECHA K, UPALA S. Vitamin D and histologic severity of nonalcoholic fatty liver disease: a systematic review and meta-analysis[J]. Dig Liver Dis, 2017, 49: 618-622. DOI:10.1016/j.dld.2017.02.003 |
[8] |
WANG N J, CHEN C, ZHAO L, CHEN Y, HAN B, XIA F Z, et al. Vitamin D and nonalcoholic fatty liver disease: bi-directional Mendelian randomization analysis[J]. EBioMedicine, 2018, 28: 187-193. DOI:10.1016/j.ebiom.2017.12.027 |
[9] |
WANG J H, XU C F, XUN Y H, LU Z Y, SHI J P, YU C H, et al. ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population[J]. Sci Rep, 2015, 5: 16494. DOI:10.1038/srep16494 |
[10] |
HOLICK M F, BINKLEY N C, BISCHOFF-FERRARI H A, GORDON C M, HANLEY D A, HEANEY R P, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline[J]. J Clin Endocrinol Metab, 2011, 96: 1911-1930. DOI:10.1210/jc.2011-0385 |
[11] |
LI L M, YOU W Y, REN W. The ZJU index is a powerful index for identifying NAFLD in the general Chinese population[J]. Acta Diabetol, 2017, 54: 905-911. DOI:10.1007/s00592-017-1024-8 |
[12] |
WANG J H, MA L, CHEN S H, XU L, MIAO M, YU C H, et al. Risk for the development of non-alcoholic fatty liver disease: a prospective study[J]. J Gastroenterol Hepatol, 2018, 33: 1518-1523. DOI:10.1111/jgh.14105 |
[13] |
JI B L, QU H, WANG H, WEI H L, DENG H C. The ZJU index: a useful indicator for recognizing insulin resistance in the Chinese general population[J]. Acta Diabetol, 2016, 53: 817-823. DOI:10.1007/s00592-016-0878-5 |
[14] |
FU C P, ALI H, RACHAKONDA V P, OCZYPOK E A, DELANY J P, KERSHAW E E. The ZJU index is a powerful surrogate marker for NAFLD in severely obese North American women[J/OL]. PLoS One, 2019, 14: e0224942. DOI: 10.1371/journal.pone.0224942.
|
[15] |
BALLESTRI S, ZONA S, TARGHER G, ROMAGNOLI D, BALDELLI E, NASCIMBENI F, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2016, 31: 936-944. DOI:10.1111/jgh.13264 |
[16] |
LEE Y S, OLEFSKY J. Chronic tissue inflammation and metabolic disease[J]. Genes Dev, 2021, 35(5/6): 307-328. |
[17] |
CLEMENTE M G, MANDATO C, POETA M, VAJRO P. Pediatric non-alcoholic fatty liver disease: recent solutions, unresolved issues, and future research directions[J]. World J Gastroenterol, 2016, 22: 8078-8093. DOI:10.3748/wjg.v22.i36.8078 |
[18] |
KARKENI E, BONNET L, MARCOTORCHINO J, TOURNIAIRE F, ASTIER J, YE J P, et al. Vitamin D limits inflammation-linked microRNA expression in adipocytes in vitro and in vivo: a new mechanism for the regulation of inflammation by vitamin D[J]. Epigenetics, 2018, 13: 156-162. DOI:10.1080/15592294.2016.1276681 |
[19] |
ABRAMOVITCH S, SHARVIT E, WEISMAN Y, BENTOV A, BRAZOWSKI E, COHEN G, et al. Vitamin D inhibits development of liver fibrosis in an animal model but cannot ameliorate established cirrhosis[J]. Am J Physiol Gastrointest Liver Physiol, 2015, 308: G112-G120. DOI:10.1152/ajpgi.00132.2013 |
[20] |
IONICA M, ABUREL O M, VADUVA A, PETRUS A, RAŢIU S, OLARIU S, et al. Vitamin D alleviates oxidative stress in adipose tissue and mesenteric vessels from obese patients with subclinical inflammation[J]. Can J Physiol Pharmacol, 2020, 98: 85-92. DOI:10.1139/cjpp-2019-0340 |
[21] |
LEUNG P S. The potential protective action of vitamin D in hepatic insulin resistance and pancreatic islet dysfunction in type 2 diabetes mellitus[J/OL]. Nutrients, 2016, 8: 147. DOI: 10.3390/nu8030147.
|
[22] |
PACIFICO L, OSBORN J F, BONCI E, PIERIMARCHI P, CHIESA C. Association between vitamin D levels and nonalcoholic fatty liver disease: potential confounding variables[J]. Mini Rev Med Chem, 2019, 19: 310-332. DOI:10.2174/1389557518666181025153712 |
[23] |
LI L H, ZHANG L, PAN S Y, WU X H, YIN X Y. No significant association between vitamin D and nonalcoholic fatty liver disease in a Chinese population[J]. Dig Dis Sci, 2013, 58: 2376-2382. DOI:10.1007/s10620-013-2658-1 |
[24] |
PATEL Y A, HENAO R, MOYLAN C A, GUY C D, PIERCY D L, DIEHL A M, et al. Vitamin D is not associated with severity in NAFLD: results of a paired clinical and gene expression profile analysis[J]. Am J Gastroenterol, 2016, 111: 1591-1598. DOI:10.1038/ajg.2016.406 |
[25] |
BARCHETTA I, DEL BEN M, ANGELICO F, DI MARTINO M, FRAIOLI A, LA TORRE G, et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial[J/OL]. BMC Med, 2016, 14: 92. DOI: 10.1186/s12916-016-0638-y.
|